Open AccessP590: PRELIMINARY SAFETY AND EFFICACY OF BGB‐11417, A POTENT AND SELECTIVE B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)
Author(s) -
Shortt J.,
Tan S. Y.,
Cannell P.,
Ng T. F.,
Fong C. Y.,
Ramanathan S.,
Rajagopal R.,
Leitch S.,
Gasiorowski R.,
Grove C.,
Lenton D.,
Tan P.,
DiNardo C.,
Ling M. T.,
Cheng S.,
Liu Y.,
Co M.,
Chan W. Y.,
Simpson D.,
Wei A. H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845248.35438.67
Subject(s) - venetoclax , azacitidine , medicine , neutropenia , regimen , oncology , myeloid leukemia , febrile neutropenia , adverse effect , refractory (planetary science) , leukemia , chemotherapy , chronic lymphocytic leukemia , biochemistry , gene expression , chemistry , physics , astrobiology , dna methylation , gene